Experts will examine the prospects of several COVID-19 vaccine candidates that are entering phase 3 trials.
MJH Life Sciences™ is offering a free webinar covering potential vaccines for the novel coronavirus disease 2019 (COVID-19) on July 30 at 6 p.m. Eastern Daylight Time (EST).
As the death toll of the COVID-19 coronavirus pandemic rises above 136,000 Americans and more than 4 million Americans have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, the country awaits the development of a vaccine and the end of the COVID-19 pandemic.
With the advancing development of a vaccine, and with legislation already being passed allowing pharmacists to administer a COVID-19 vaccine, the United States’ most accessible health care professionals must remain preparedand informed on budding phase 3 trials and leading research. The webinar will also discuss how to combat logistical challenges associated with rolling out a vaccine in the middle of a pandemic.
The 1-hour webinar will confront the race for a vaccine and feature experts on viruses and vaccines who will delve into the research at the forefront of COVID-19 vaccine development.
Click here to register for the free event
The panel for this webinar features:
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Pfizer Announces Positive Top-Line Data for Abrysvo Immunization in Adults Aged 18 to 59 Years
April 9th 2024Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.